- TransCode Therapeutics (RNAZ) to present Phase 1a data for TTX-MC138 at ESMO 2026 on Oct 23.
TransCode Therapeutics (RNAZ) announced a poster presentation at ESMO Congress 2026 on October 23, highlighting Phase 1a clinical data for TTX-MC138, a first-in-class antagomiR targeting miR-10b in advanced solid tumors. The company is also evaluating TTX-MC138 in a Phase 2a trial under the PRE-I-SPY program.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.